CBLB and cancer: Recent preclinical studies have highlighted the possibility that inhibiting Cbl-b could substantially enhance antitumor immune activities (25), prompting the initiation of early clinical trials to explore its viability as a target for cancer immunotherapy (NCT05107674, NCT05662397).